The management of multiple myeloma in 2021

Claudio Cerchione, MD, PhD, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Italy, gives an overview of the treatment landscape for multiple myeloma, highlighting recent advances in frontline therapy, including the introduction of daratumumab-based approaches in both transplant-eligible and transplant-ineligible patients. Dr Cerchione also discusses updates in the treatment of myeloma in the relapsed/refractory setting, commenting on the use of monoclonal antibody combinations such as belantamab mafodotin, carfilzomib and ixazomib, and the promise of the novel combination of belantamab mafodotin and selinexor. Finally, Dr Cerchione talks on the potential future role of bispecific antibodies and chimeric antigen receptor T-cell (CAR-T) therapy. This interview took place at the virtual European Hematology Association (EHA) Congress 2021.